Farmakoterapia w Psychiatrii i Neurologii

Full text

2/2025 vol. 41
Review article

Aripiprazole and cariprazine in the augmentation of treatment-resistant depression: A review of efficacy, tolerability, and clinical applications

Konrad R. Puchalski 1
,
Cezary Orzechowski 2
,
Natalia Radwańska 2
,
Patrycja Janowiecka 3
,
Weronika Skoczek 2
  1. Provincial Specialist Hospital in Wroclaw, Wroclaw, Poland; Wojewódzki Szpital Specjalistyczny we Wrocławiu, Wrocław, Polska
  2. Medical University of Warsaw, Warsaw, Poland; Warszawski Uniwersytet Medyczny, Warszawa, Polska
  3. Poznan University of Medical Sciences, Poznan, Poland; Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Poznań, Polska
Farmakoterapia w Psychiatrii i Neurologii 2025
DOI: https://doi.org/10.5114/fpn.2025.159506
Data publikacji online: 2026/04/28
Article file
Aripiprazole and cariprazine in the augmentation of treatment-resistant depression- A review of effi
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Ainsworth NJ, Brender R, Gotlieb N, Mulsant BH, Blumberger DM, Karp JF et al. Association between lean muscle mass and treatment-resistant late-life depression in the IRL-GRey randomized controlled trial. Int Psychogeriatr 2023; 35: 707-716.
  2. Ali E, Latif F, Mashkoor Y, Gul Z, Malik F, Hanif M et al. Role of adjunctive cariprazine for treatment-resistant depression in patients with major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. Asian J Psychiatry 2024; 95: 104005.
  3. Altmann HM, Kazan J, Gebara MA, Roose SP, Karp JF, Lenze EJ et al. Predicting Medication Nonadherence in Older Adults With Difficult-to-Treat Depression in the IRL-GRey Randomized Controlled Trial. Am J Geriatr Psychiatry 2022; 30: 994-1002.
  4. Bai B, Li Y, Chen X, Wang Y, Zhang K, Zhang X et al. The augmentative efficacy of second-generation anti-psychotics (SGA) to anti-depressants in treating treatment-resistant depression: a network meta-regression analysis. BMC Psychiatry 2025; 25: 338.
  5. Beunk L, Nijenhuis M, Soree B, van der Sijs H, Guchelaar HJ, van Schaik RHN et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics. Eur J Hum Genet 2024; 32: 278-285.
  6. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009; 14: 197-206.
  7. Durgam S, Earley W, Guo H, Li D, Németh G, Laszlovszky I et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry 2016; 77: 371-378.
  8. Earley WR, Guo H, Németh G, Hincapie-Castillo JM, Herman BK, McIntyre RS. Cariprazine augmentation to antidepressant therapy in major depressive disorder: Results of a randomized, double-blind, placebo-controlled trial. Psychopharmacol Bull 2018; 48: 62-80.
  9. Fava M, Durgam S, Earley W, Lu K, Hayes R, Laszlovszky I et al. Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 2018; 33: 312-321.
  10. Fava M, Masand PS, Maletic V, Christensen M, Szatmári B, Barabássy A et al. Efficacy of Adjunctive Cariprazine on Anxiety Symptoms in Patients With Major Depressive Disorder: Post Hoc Analysis of a Randomized Placebo-Controlled Trial. J Clin Psychiatry 2025; 86: 24m15506.
  11. Gebara MA, DiNapoli EA, Kasckow J, Karp JF, Lenze EJ, Mulsant BH et al. Specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression. Int J Geriatr Psychiatry 2018; 33: e330-e335.
  12. Guidetti C, Chaikali S, Trivedi MH, Shelton RC, Papakostas GI, Fava M et al. Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD). J Affect Disord 2025; 390: 119836.
  13. Hsu JH, Mulsant BH, Lenze EJ, Karp JF, Reynolds CF, Blumberger DM et al. Impact of Prior Treatment on Remission of Late-Life Depression with Venlafaxine and Subsequent Aripiprazole or Placebo Augmentation. Am J Geriatr Psychiatry 2016; 24: 918-922.
  14. Ji M, Feng J, Liu G. Efficacy and safety of aripiprazole or bupropion augmentation and switching in patients with treatment-resistant depression or major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. PLoS One 2024; 19: e0299020.
  15. Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis. Psychol Med 2023; 53: 4064-4082.
  16. Lenze EJ, Mulsant BH, Roose SP, Lavretsky H, Reynolds CF, Blumberger DM et al. Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression. N Engl J Med 2023; 388: 1067-1079.
  17. McIntyre RS, Maletic V, Masand P, Christensen M, Szatmári B, Barabássy A et al. The effect of adjunctive cariprazine on symptoms of anhedonia in patients with major depressive disorder. J Affect Disord 2025; 385: 119366.
  18. Milosavljevic F, Bukvic N, Pavlovic Z, Miljevic C, Peusic V, Molden E et al. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. JAMA Psychiatry 2021; 78: 270-280.
  19. Nuñez NA, Joseph B, Pahwa M, Kumar R, Resendez MG, Prokop LJ et al. Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. J Affect Disord 2022; 302: 385-400.
  20. Papakostas GI, Trivedi MH, Shelton RC, Iosifescu DV, Mathew SJ, Fava M et al. Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. Mol Psychiatry 2024; 29: 2287-2295.
  21. Pozuelo Moyano B, Gomez Bautista D, Porras Ibarra KJ, Sanchez-Mico M, Lopez-Diaz A, Giner L et al. Systematic review of clinical effectiveness of interventions for treatment resistant late-life depression. Ageing Res Rev 2025; 107: 102710.
  22. Riesenberg R, Yeung PP, Rekeda L, Earley W, Németh G, Fava M. Cariprazine for the Adjunctive Treatment of Major Depressive Disorder in Patients With Inadequate Response to Antidepressant Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry 2023; 84: 22m14643.
  23. Sachs GS, Yeung PP, Rekeda L, Earley W, Németh G, Fava M. Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A randomized, double-blind, placebo-controlled phase 3 study. Am J Psychiatry 2023; 180: 241-251.
  24. Scott F, Hampsey E, Gnanapragasam S, Strawbridge R, Young AH. Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. J Psychopharmacol 2023; 37: 268-278.
  25. Seshadri A, Wermers ME, Habermann TJ, Singh B. Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis. Prim Care Companion CNS Disord 2021; 23: 20r02799.
  26. Takeshima M, Umakoshi A, Omori Y, Kikuchi Y, Tsuda H, Akechi T. et al. Impact of aripiprazole discontinuation in remitted major depressive disorder: a randomized placebo-controlled trial. Psychopharmacology 2024; 241: 1555-1563.
  27. Wang J, Li W, Li M, Wu Y, Zhu Y. Comparative efficacy and safety of 4 atypical antipsychotics augmentation treatment for major depressive disorder in adults: A systematic review and network meta-analysis. Medicine (Baltimore) 2023; 102: e34670.
  28. Yan Y, Yang X, Wang M, Zhao L, Zhang Y, Zhang Q et al. Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis. Psychol Med 2022; 52: 2224-2231.
SUBMIT YOUR PAPER
Share
without publication fees
without publication fees
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications